Recognition from Medidata for our support of clients’ site selection
New York – November 8, 2023 – Medidata recognized Catalyst Clinical Research at Medidata NEXT New York 2023 on Nov. 7 for its efforts with artificial intelligence (AI). Nick Dyer, Chief Executive Officer for Catalyst Clinical Research, accepted the Medidata NEXT 2023 AI in Support of Drug Development Award, which underscores the work Catalyst does in support of clinical trial site selection that helps clients to bring life-altering therapies to patients.
“We are proud to be recognized by Medidata for our leading-edge use of the Intelligent Trials tool. We leverage the consolidated trial data and AI to inform our site selection process,” said Nick Dyer. “This gives Catalyst deep insights into historical performance and current trial volume so we can plan most effectively with sites we recommend for each trial.”
In October, Medidata, a Dassault Systèmes company and leading provider of clinical trial solutions to the life sciences industry, announced a multi-year partnership expansion with Catalyst Clinical Research to support Catalyst Oncology, a specialist oncology clinical research organization.
About Catalyst Clinical Research
Catalyst is a clinical research organization (CRO) that provides highly customizable solutions to the global biopharmaceutical industry through two established, branded solutions: Catalyst Oncology and Catalyst Flex. The company provides full-service oncology CRO offerings through Catalyst Oncology and multi-therapeutic Client- or Catalyst-managed functional services through Catalyst Flex. With over 1000 staff and offices in the United States, Europe, and Asia-Pacific regions, Catalyst’s flexible service model is built from more than a decade of listening to customers, devising customer-centric solutions, and helping customers drive breakthrough clinical studies by leveraging expert teams and innovative technologies. Visit Catalyst online at CatalystCR.com. Follow us LinkedIn: @CatalystCR.
Catalyst is a portfolio company of QHP Capital, a leading healthcare and life sciences investment firm.
Medidata is powering smarter treatments and healthier people through digital solutions to support clinical trials. With over 20 years of groundbreaking technological innovation across more than 30,000 trials and 9 million patients, Medidata offers industry-leading expertise, analytics-powered insights, and the largest patient-level historical clinical trial data set in the world. More than 1 million registered users across 2,100+ customers trust Medidata’s seamless, end-to-end platform to improve patient experiences, accelerate clinical breakthroughs, and bring therapies to market faster. The company is a wholly owned subsidiary of Dassault Systèmes (Euronext Paris: FR0014003TT8, DSY.PA), which with its 3DEXPERIENCE platform is positioned to lead the digital transformation of life sciences in the age of personalized medicine with the first end-to-end scientific and business platform, from research to commercialization. Medidata is headquartered in New York City and has been recognized as a Leader by Everest Group and IDC. Discover more at www.medidata.com and follow us @Medidata.